Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hamsa Subramanian

Allergy & Immunology Saint Louis, MO Medical Doctor

NPI 1154370203 CMS profile 233048

425 N New Ballas Rd Ste 203, Saint Louis, MO 63141

Open in the dashboard

General payments

$4,567

80 records reported · program years 2019–2025

Research payments

$7,901

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,142 paid to institutions, not to them · program year 2020

Through program year 2025, Hamsa Subramanian of Saint Louis, MO is reported in the CMS Open Payments database as having received $4,567 across 80 general payments and $7,901 in research payments paid to them. Separately, studies naming them as principal investigator received $11,142 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 77th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $379 17
2024 General $317 13
2023 General $226 14
2022 General $2,382 22
2021 General $932 7
2020 General $111 1
2020 Research $7,901 2
2019 General $221 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hamsa Subramanian
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Hamsa Subramanian were reported at $379. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Hamsa Subramanian Allergy & Immunology median Middle half National median
2019 $221 $594 $163–$1,512 $163
2020 $111 $426 $106–$1,233 $114
2021 $932 $638 $157–$1,708 $132
2022 $2,382 $790 $205–$1,961 $149
2023 $226 $852 $220–$2,147 $160
2024 $317 $865 $203–$2,267 $164
2025 $379 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Healthcare Solutions, Inc. $1,715 5 payments
  2. Octapharma USA, Inc. $769 2 payments
  3. GlaxoSmithKline, LLC. $346 10 payments
  4. AstraZeneca Pharmaceuticals LP $259 11 payments
  5. Genzyme Corporation $207 7 payments
  6. OptiNose US, Inc. $187 3 payments
  7. Aimmune Therapeutics, Inc. $175 1 payment
  8. Takeda Pharmaceuticals U.S.A., Inc. $169 10 payments
  9. Pfizer Inc. $140 7 payments
  10. AbbVie, Inc. $127 5 payments
  11. Other $473 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,914 74 payments
  2. Consulting Fee $1,659 2 payments
  3. Honoraria $925 2 payments
  4. Education $69 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $1,715 5 payments
  2. CUTAQUIG $769 2 payments
  3. DUPIXENT Immunology $342 10 payments
  4. Xhance $187 3 payments
  5. PALFORZIA $175 1 payment
  6. CUVITRU $154 9 payments
  7. RINVOQ $127 5 payments
  8. FASENRA $122 3 payments
  9. NUCALA Immunology $119 8 payments
  10. NUCALA Respiratory $111 1 payment
  11. Other $736 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,901 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,332

Median for Allergy/ Immunology: 449

Drug cost

$905,622

Median for Allergy/ Immunology: $169,700

Branded share of claims

32.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Orladeyo Berotralstat Hydrochloride Brand 12 $494,157
Xolair Omalizumab Brand 27 $80,743
Dupixent Pen Dupilumab Brand 16 $61,274
Dupixent Syringe Dupilumab Brand 13 $50,232
Nucala Mepolizumab Brand 12 $49,006
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 62 $44,369
Breo Ellipta Fluticasone/Vilanterol Brand 72 $36,763
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 44 $29,989
Arnuity Ellipta Fluticasone Furoate Brand 38 $13,279
Advair Hfa Fluticasone Propion/Salmeterol Brand 29 $10,276

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$139,941

Of which drugs: $79,899

Medicare patients

233

Average age 72

Services billed

8,134

172 women, 61 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 56%
Depression 28%
Diabetes 27%
Ischemic heart disease 24%
COPD 19%
Osteoporosis 19%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,064
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 11 30 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $69
$69 29 —
NUCALA
  • GlaxoSmithKline, LLC. $38
$38 12 —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $27
$27 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $18
$18 — —
OCTAGAM IMMUNE GLOBULIN (HUMAN)
  • PFIZER INC. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record